NK cell therapy for advanced solid tumors
Part of Cancer, Digestive system, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a new immune cell therapy called NK521 for people with advanced solid tumors like liver or ovarian cancer that have not responded to standard treatment. The therapy may be given as an infusion or into the belly (for those with fluid buildup containing cancer cells).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced solid tumor (like liver or ovarian cancer) that came back or didn't respond to at least one standard treatment.
- You have at least one tumor that can be measured on a CT or MRI scan.
- You are physically able to care for yourself (ECOG score 0-2) and have a life expectancy of at least 3 months.
- If you are of childbearing age, you must not be pregnant or breastfeeding and must use birth control during and for 6 months after treatment.
- You have no severe heart disease, active infections (like HIV, hepatitis B or C), or recent use of certain other cancer treatments or immune-suppressing drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new therapy that uses your own natural killer (NK) cells, modified to better fight cancer and injected directly into your abdomen. It's for people with advanced ovarian cancer who cannot have surgery or whose tumor cannot be fully removed.
This trial tests a new type of immune cell therapy (CIML NK cells) given directly into the abdomen for women with ovarian cancer that has come back and is now resistant to standard platinum chemotherapy. The goal is to see if these specially trained cells can fight the cancer safely.
This trial tests a new type of cell therapy (natural killer cells) made from a donor, combined with low-dose IL-15 (a protein that helps these cells work) and sometimes with pembrolizumab (Keytruda), for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this combination can shrink tumors or slow their growth.
This trial tests a new natural killer (NK) cell therapy, NK510, for people with advanced non-small cell lung cancer who have already tried immunotherapy and it stopped working. The goal is to see if NK510 is safe and can shrink tumors or slow the cancer's growth.
This trial studies an experimental cell therapy called NK510 for people with advanced stomach or colorectal cancer that has not responded to standard treatments. The therapy uses natural killer cells, a type of immune cell, to attack the cancer. It may help slow or stop the cancer's growth.
This early-stage trial tests NK521, a new immunotherapy infusion, for patients with advanced solid tumors (like liver, stomach, or colon cancer) that have spread and caused fluid buildup in the belly. The goal is to see if NK521 can help shrink tumors and improve survival when standard treatments have stopped working.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.